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 Foreword: Euro HIV Index 2009 – a reality check for Europe 
In every context HIV/AIDS is an alarming disease. It could be hoped that after a quarter of a 
century of high-profiled counter-action the situation would be under control in Europe. But 
that is hardly the case. 
Still the number of cases is rising. A growing number of people in Europe are living with 
HIV. One reason of course is that HIV today has become a chronic condition with a 
significantly improved survival span. This is a clear sign of the impact from efficient 
medication and treatment. But this fact would feel more comforting if we knew the real 
number of infected people and how to reach out to them. Here is one of the strange aspects of 
European HIV care: 
While often keeping excellent track of other contagious diseases such as TB or gonorrhea the 
national and EU authorities miss out when it comes to reporting reliable numbers on HIV-
infected individuals, data which after decades of supposed compulsory reporting is still 
uncertain in every country in Europe. The estimates seem to shift significantly between data 
sources, which is worrying. The number of undetected cases is also not available, which is 
more understandable, even though there are some attempts to estimate these numbers. Given 
the estimates of how migration from outside of the EU will develop, the lack of knowledge 
with regards to incidence and undetected cases is alarming. 
Successful action against HIV/AIDS (and illnesses often related to HIV) requires deep and 
sustainable interaction between public policy, healthcare, education and civil society. Not 
least the HIV community has become a more and more important actor. Here are many 
impressive examples to find. Still it is easier to measure the input of healthcare resources than 
the outcome, a structural problem to handle to make efficient treatment accessible to 
everybody around Europe. The Euro HIV Index illustrates the inequalities in HIV care and in 
societal conditions around the European Union. Such inequalities challenge not only the 
survival among people with HIV/AIDS but also the EU principles of equity and solidarity. 
This Index wants to be a reality check putting official plans and policy in contrast to actual 
outcomes. HIV is a field full of ambitious documents and conferences but somewhat less hard 
facts and ongoing assessment of performance. The Health Consumer Powerhouse finds it 
constructive to contribute by this comparison and analysis, trying to provide a from-below 
contribution. The work has been developed in interaction with the patient groups EATG and 
AEE and a wide range of consulting with national authorities, international organisations and 
the HIV community. We hope for a vivid discussion on the Index findings and for a broad 
exchange of ideas to advance and implement this “reality check” approach and instrument. 
The Index report is the initial step, we hope to be able to continue working on the 
development and implementation of good policy. 
The Index work has been supported by an unrestricted educational grant by Gilead Science. 
The Index is presented under the auspices of the Swedish EU Presidency 2009. 
Brussels October 13, 2009 
Johan Hjertqvist 
President 
Health Consumer Powerhouse 
Stockholm/Brussels/Winnipeg
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1.  Index champions and key outcomes  
1.1  What characterizes the best HIV care?  
To have a good HIV care the system have to be able to reach many different groups of 
population, especially the ones having  higher risk of getting infected. These included 
IDU (injecting drug users), Sex workers, marginal and migrant populations, especially 
undocumented migrants, men having sex with men (MSM), and prisoners. The best way 
to take care of these groups to achieve good outcomes starts with good prevention 
programs and good access to care.  
Luxembourg is the absolute winner of the Euro HIV index 2009 with 857 points out of 
the possible 1000, 66 point above the second in the ranking. It performs very well in three 
out of the four sub-disciplines. They established very effective prevention programmes 
and access to care. On the other hand, there is some room for improvement on outcomes. 
Luxembourg needs to reach the undiagnosed population better and faster because some 
patients are starting treatment too late. It is also true that Luxembourg has a lot of cross-
border immigration, which is very difficult to control and to follow up. This makes 
reaching these groups of people more difficult. 
The second in the ranking is Malta which scores 791 points, a slight surprise! Malta is 
doing rather well in all four sub-disciplines. The total number of HIV/AIDS cases is still 
small compare with other countries but growing fast. At this moment prevention and 
access should be the main areas for increased efforts, especially as in recent years the 
number of people infected in the island has quadrupled, and half of the HIV cases being 
treated in Malta involve African immigrants. There would be a risk that such good 
performance deteriorates in the near future because of lack of financial support and 
human resources. 
Third and fourth positions are occupied by Switzerland (774) and Finland (763), both 
countries having very good prevention strategies. Switzerland is one of the countries were 
the highest number of people were prosecuted and convicted because of exposure and 
transmission of HIV. They are currently working on a new law that hopefully will be 
implemented during 2012, in which only those cases of intentional exposure and 
transmission would be prosecuted. They have made a very solid cohort study on all 
aspects of HIV prevention, detection, care and support, but to obtain data from this study 
is complicated and needs an approval. Finland has some problems with the performance 
of their monitoring system and these can explain their modest performance in outcomes, 
Finland not being able to provide quality data on two out of the six indicators. Finland is 
also one of the countries were patients complain most about discrimination at work.  
In fifth position is The Netherlands with 760 points. The NL also have very good 
prevention programmes running, and take very good care of the situation through on-
going analysis of the situation. It is important to highlight the great job done by the HIV 
monitoring foundation, which coordinates the whole registration of the disease from 
Amsterdam, a very good example to be copied by others. 
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1.2 General observations. The current situation of HIV in Europe 
At the end of 2007 it was estimated that around 800,000 people were living with HIV in 
Western and Central Europe. This represents 8.1 % increase over the estimated 740,000 
in 2006. Although the number of people living with HIV and AIDS in Europe is relatively 
small when compared to the number of people living with HIV in areas such as Asia and 
sub-Saharan Africa, HIV/AIDS in Western and Central Europe is still considered a major 
public health issue. The highest rates were reported from Estonia, Portugal and Latvia; 
the lowest rates were reported by Slovakia, the Czech Republic and Romania.  
The number of people dying from AIDS in this region has significantly decreased since 
the introduction of combination antiretroviral treatment in the mid-1990s. Most Western 
and Central European countries benefit from wealthy economies, stable infrastructures 
and developed healthcare systems, making significant progress in scaling up towards 
universal access, including access to antiretroviral therapy and prevention of mother-child 
transmission. HIV is now often considered a chronic disease, instead of a death sentence. 
Heterosexual intercourse has become the predominant mode of transmission in persons 
diagnosed with HIV in recent years in most countries and accounted for over 50% of the 
cases reported in 2006. Most of the increase in HIV diagnoses among heterosexuals is 
among persons originating from infected high-prevalence countries outside Europe, 
primarily in sub-Saharan Africa. Data from several countries suggest that the majority of 
these persons have been infected in their country of origin, although transmission within 
the host EU country does occur. 
The number of reported HIV diagnoses among MSM has nearly doubled over the past 5 
years. MSM (Men having sex with men) account for the largest number of new diagnoses 
in a number of countries including Germany, The Netherlands and Greece. 
The spread of HIV among Injecting drug users (“IDU”) has declined substantially in 
Western Europe, following a peak in incidence in the mid- to late 1980s which could be 
explained by the increasing availability of harm reduction measures, such as needle 
exchange programmes. However, the transmission of HIV among IDUs is still an 
important factor in some countries of the EU, including Italy, Portugal, Spain and Poland.  
Mother-to-child transmission (MTCT) has dropped significantly with the wide 
implementation of screening of pregnant women and prevention strategies.  
Experts share the concern that the commitment to HIV prevention remains inadequate, as 
the incidence of new infections is far higher than the number of people that have access or 
will be able to have access to treatment. Combination prevention strategies should be 
scaled up. There is an urgent need to step up the development and implementation of 
comprehensive prevention approaches, including increased access to male and female 
condoms as well as information, education and awareness-raising, along with continued 
investment in research and development of new prevention technologies. 
There is a need to overcome legal, regulatory and cultural or other barriers that inhibit 
access to effective HIV prevention, treatment, care and support, including medicines, 
commodities and services for people living with HIV/AIDS and the populations most at 
risk, including men who have sex with men, sex workers and injecting drug users. People 
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affected by HIV/AIDS should be fully involved in the design, implementation and 
monitoring of country strategies to confront the disease. 
1.3 Areas for HIV care improvement 
1.3.1  Lack of leadership 
Significant advances in the response to HIV have been achieved when there was strong 
and committed leadership. Leaders are distinguished by their action, innovation and 
vision; their personal example and engagement of others; and their perseverance in the 
face of obstacles and challenges,” said the World AIDS Campaign. “Leadership must be 
demonstrated at every level to get ahead of the epidemic – in families, in communities, in 
countries and internationally.”  The overall purpose of the World AIDS Campaign from 
2005 to 2010 was to ensure that leaders and decision makers deliver on their promises on 
AIDS, including the provision of Universal Access to Treatment, Care, Support and 
Prevention services by 2010. That year is approaching and the goals are not fully reached, 
in part because of the lack of leadership.  
1.3.2 The three ones: 
(see Section 7.6.1, indicator 1.7) 
The first time we asked national bodies about the implementation of “The three ones” in 
their countries, they were happy to reply “yes of course, we had all of them ready and 
running”, later on when we asked around we realize that those answers were in general 
not too accurate, it seems implementation means very different quality standards 
depending on the country. Some countries develop national plans that already expired 
without having a new plan ready for example. Additionally it is often the case that there is 
not a “true National AIDS Coordinating authority with multisector participation and 
mandate” it is normal to hear complains about not meeting enough or having too little 
social participation. And in general the coordinating authorities are not independent 
enough, as it was the original idea, to make real actions and take important decisions 
without external influence.  
The monitoring and evaluation systems are of very different quality too, even though 
there are some very good examples in Europe, where Denmark and The Netherlands 
could be highlighted. 
 
1.3.3 HIV Data  
Good data is missing in Europe and for example, the true number of HIV-infected 
individuals is unknown in every country (see Section 7.7.1). Prevalence numbers are 
estimates rather than real numbers, especially in those countries where recording systems 
are working with several limitations. 
The number of cohort studies existing in Europe, plus international collaborations like 
Eurosida, would make the general public think there would be no problems finding 
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epidemiological data for HIV. However, restrictions to obtain data coming from these 
sources exist in many countries.   
1.3.4  Stigma and Discrimination 
These are daily realities for people living with HIV and especially for those not only 
living with HIV but belonging to groups particularly vulnerable to be marginalized, 
including sex workers, men who have sex with men, people who inject drugs, prisoners 
and migrants.  
Discrimination can occur at all levels of a person’s daily life, for example, when they 
wish to travel, use healthcare facilities, go to school or get a new job. In Europe, where 
injecting drug use and sex between men have been the most common sources of infection, 
these behaviours are highly stigmatised. 
General public but also national legislation, rules and policies regarding HIV/AIDS can 
have a significant effect on the lives of people living with HIV/AIDS (PLWH). 
Discriminatory practices can alienate and ostracise PLWH, reinforcing the stigma 
surrounding the disease. E.g., in the UK, the legal system can prosecute individuals who 
pass the virus to somebody else, even if they did so without intent or knowledge of their 
condition. Many debates will be needed to come to a common point to solve the current 
situation about Criminalization of HIV. 
1.3.5 Universal access to care and treatment 
 European states have committed to ensure the right to health, which is considered a 
fundamental human right to which all people are entitled regardless of their status or 
citizenship. Current policy and practice however do not always reflect these 
commitments.  Health care services and HIV prevention, treatment and care programmes 
are too scarce and often do not meet the specific needs of migrants and ethnic minorities. 
Restrictive legislation, social exclusion and stigmatisation lead to instability and 
vulnerability for migrants and ethnic minorities. They are often confronted with policies 
which lead to marginalisation, reinforce xenophobia and racism and result in a worrying 
level of exclusion.  This affects not only their legal and socio-economic situation but also 
their access to healthcare, especially HIV prevention, treatment, care and support.  
It is estimated that about 30% of people living with HIV are unaware of their condition. 
High priority should be given to scaling up HIV testing and counseling, to maximize the 
opportunities of reaching those with HIV infection or at high risk of infection. When 
HIV-infected persons are diagnosed with HIV infection, there is a need to ensure that 
these persons are linked to HIV treatment, care and support. 
1.3.6 Situation in Prisons 
Prevalence of HIV infection among prisoners in many countries is significantly higher 
than in the general population. The risk of being infected in prison, specifically through 
the sharing of contaminated injecting equipment, is high. Even the countries that made 
the biggest efforts to prevent the use of drugs have not been 100% successful. An 
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increasing number of countries have introduced HIV programmes in prisons since the 
early 1990s. However, many of these programmes exclude necessary interventions such 
as needle exchange (or as an alternative bleach provision to disinfect needles) methadone 
treatment or free condoms distribution. 
All HIV testing, including testing in prisons and detention centres but also for sex 
workers, must be voluntary and be accompanied by appropriate pre- and post-test 
counselling. Test results must be kept confidential. Mandatory HIV testing is unethical, 
increases HIV-related stigma, and undermines HIV education and prevention efforts. 
(Migration and HIV/AIDS: community recommendations; www.eatg.org ) 
1.3.7 Sexual education and prevention efforts. 
As sexual transmission is one of the main means of HIV transmission in Europe, it is 
crucial to ensure that sexual and reproductive health services and HIV initiatives are 
integrated. Prevention, treatment and care have to go beyond the provision of HIV 
services and should include, among others, education programmes, counselling on safer 
sex, contraception, pregnancy and birth. Programmes should be designed to reach the 
greatest number of people possible. In this context, special attention should be paid to 
women, mothers and young girls from migrant and ethnic communities, who are often 
extremely vulnerable and confronted with multiple sources of discrimination and 
exclusion. The approaches should be designed to reach as many people as possible, 
respecting the different educations and cultural backgrounds. 
Unlike HIV, many STDs can be treated and cured relatively easily and cheaply if 
diagnosed early enough. To fight these epidemics, authorities must act to expand access 
to testing and treatment facilities; to educate people about safer sex and risk reduction; 
and to counter the prejudice surrounding STD infections. The massive use of 
contraceptive pills used in central and north European countries instead of condoms it is 
promoting the transmission of different sexual diseases, as Chlamydia. A lot more 
information among general public, especially to young people is needed. 
1.3.8 HIV-TB co-infection: 
This report will mention many times the necessity of collaboration between HIV and 
Tuberculosis professionals to control the HIV-TB co-infection growing in Europe.  HIV 
infection has contributed to a significant increase in the worldwide incidence of 
tuberculosis. Although HIV-related tuberculosis is both treatable and preventable, 
incidence rates continue to climb in developing nations where HIV infection and 
tuberculosis are endemic and resources are limited. Worldwide, tuberculosis is the most 
common opportunistic infection affecting HIV-seropositive individuals. TB is harder to 
diagnose in people living with HIV and it is the only major AIDS-related opportunistic 
infection that poses a risk to HIV-negative people. Additionally, it is one of the most 
common causes of death in patients with AIDS in Europe. 
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1.3.9 Prevent HIV infection in migrant populations 
More international cooperation among neighbouring countries to prevent HIV infection in 
migrant populations would be desirable. There are large numbers of migrant populations 
in Europe, moving permanently from city to city and from country to country. It is not 
rare to hear of sex workers coming from Slovakia into Austria to work there and then 
going back, or sex workers living in Belgium but working in Luxembourg and being 
originally from Ukraine. Also injecting drug users move from Lithuania to Estonia or 
Latvia, etc. The HCP research found some collaborations or programmes running 
between countries to prevent international HIV transmission, but these are certainly not 
enough. 
 
 
2.  Background 
The Health Consumer Powerhouse (HCP) promotes plans and actions related to consumer 
healthcare in Europe. Tomorrow’s health consumer will not accept any traditional 
borders. To become a powerful actor, building the necessary reform pressure from below, 
the consumer will need access to knowledge to compare health policies, consumer 
services, and quality outcomes. HCP wants to add to this development.  
Since 2004, the HCP has published the Swedish Health Consumer Index 
(www.vardkonsumentindex.se, also in an English translation). By ranking the 21 county 
councils using 12 basic indicators concerning the design of ”systems policy”, consumer 
choice, service level, and access to information, we introduced benchmarks so consumers 
can evaluate healthcare options.  
For the pan-European generalist indexes in 2005 – 2009, HCP has followed the same 
approach, selecting a number of indicators describing to what extent the national 
healthcare systems are “user-friendly”, providing a basis for comparing different national 
systems. The HCP is now benchmarking healthcare in 34 countries. 
HCP advocates that quality comparisons within the field of healthcare are a true win-win 
situation: the consumer can use the information to make an informed choice and 
governments, authorities, and providers can use the information to improve consumer 
satisfaction and quality outcomes. With such a view, the Euro HIV Index2009 is designed 
to become an important benchmark system that supports interactive assessment and 
improvement. 
 
2.1  About the authors 
Project Management for the Euro HIV Index2009 was executed by Beatriz Cebolla, 
Ph.D. 
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Dr. Cebolla was born in Madrid in 1975, where she graduated in biochemistry (1998), 
after spending her last year in Berlin where she finished in parallel her Diploma at the 
TU-Berlin.  
She went back to Madrid to work at the Biomedical Research Institute (IIB/CSIC) and 
finished in 2004 her PhD in Neuroscience. At the beginning of 2005, she received a 
postdoctoral fellowship at the Institute for Molecular Pathology (IMP) in Vienna to work 
in Dr. Busslinger's laboratory in the stem cells field.  
In total, she has worked as a researcher for more than 10 years, being attached to various 
institutions and projects relevant to the healthcare field.  
She joined the Heath Consumer Powerhouse in 2007, where she works as a senior project 
manager.  She was Project Manager for the European Diabetes Index presented in 
September 2008; she will soon finish a Master in Public Health in which the topic of the 
final project is going to be quality assurance in health care. 
 
Arne Björnberg, Ph.D., Vice President Production, R&D for the HCP. 
Dr. Björnberg has previous experience from Research Director Positions in Swedish 
industry. His experience includes serving as CEO of the Swedish National Pharmacy 
Corporation (Apoteket AB), Director of Healthcare & Network Solutions for IBM Europe 
Middle East & Africa, and CEO of the University Hospital of Northern Sweden 
(Norrlands Universitetssjukhus, Umeå).  
Dr. Björnberg was also the project manager for the Euro Health Consumer Index 2005 – 
2009 projects as well as other projects from the Heath Care Powerhouse as the Euro 
Consumer Heart Index. 
 
 10 
 
 
Health Consumer Powerhouse 
Euro HIV Index 2009 report 
3.  Results of the Euro HIV Index 2009 
 
 11 
 
 
Health Consumer Powerhouse 
Euro HIV Index 2009 report 
Indicators with Low/Medium/High weights are indicated in the final score matrix by small, 
medium size and large circle symbols respectively (see Section 7.2.4). 
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3.1  Results summary: what country provides the best HIV care?  
Luxembourg is the winner of the Euro HIV Index 2009, scoring 857 points out of a 
maximum of 1000 points. This country performs extremely well in every sub-discipline 
except Outcomes where there is some room for improvement. 
Malta is the surprise of the index in second position with 791 points, for the first time in 
the top five in a HCP Index. Malta performs well on outcomes, but needs to improve in 
involvement and rights and also in access. As the number of immigrants is increasing new 
cases in the island, to get better access to care is going to be one of the key points for their 
future performance. 
 
Next in the ranking is Switzerland (775), almost perfect in Prevention but rather more 
very modest on Access, especially regarding undocumented migrants. HIV 
criminalization is one of the important issues to be changed in the near future in 
Switzerland to improve the rights of PLWH; in principle a new law is ready only waiting 
to be approved. 
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4. What do the HIV Index 2009 results reveal? 
4.1  Sub-discipline: Involvements and rights 
 
“Since the beginning of the epidemic, stigma, discrimination, and gender inequality have 
been identified… as major obstacles to effective responses to HIV. There has never been 
serious political and programmatic commitment to doing anything about them.” 
 
– Peter Piot, Executive Director, Joint United Nations Programme on HIV/AIDS  
 
 
Reducing HIV Stigma and Discrimination is a critical part of national AIDS programmes 
all over the world.  
Most complaints about stigma and discrimination of people living with HIV in Europe 
concern issues of schools, work settings and rejection by Non-HIV doctors or clinics, 
particularly dentists and surgeons. To avoid these problems, many NGOs and other 
institutions provide list of doctors who accept HIV positive patients. Sometimes this issue 
is so well known that national institutions are providing this information. 
In most countries, there are laws put in place to assure children the right to school 
attendance, or laws that enforce data protection; however there are still countries in which 
a private school has ways to reject a student for being HIV positive, or schools where 
general HIV screening programmes for kids are established and allowed. Cases in which 
private/confidential data has been unofficially shared are known. 
Criminalization of HIV is under debate in Europe: Which should be the best way to judge 
a person that transmit or expose others to HIV? Which facts should be taken into 
account? Under which circumstances should the offender be educated rather than 
prosecuted?  
Careful consideration should be given to the fact that HIV-specific criminal legislation 
can further stigmatize persons living with HIV, provide a disincentive to HIV testing; 
create false sense of security among people who are HIV-negative, and, rather than 
helping women by protecting them against HIV infection, impose on them an additional 
burden and risk of violence or discrimination (UNAIDS, 2007), However, HIV-specific 
laws still exist in high number of countries in Europe like; Demark, Germany, 
Switzerland, Netherlands, Slovakia, Portugal and Poland. There is no evidence that 
criminal laws specific to HIV transmission make any significant impact on the spread of 
HIV or on halting the epidemic. Therefore, priority must be given to increasing access to 
comprehensive and evidence-informed prevention methods in the fight against 
HIV/AIDS. Such measures include providing HIV information, support and commodities 
to people so they can avoid exposure to HIV through practicing safer behaviors;  
increasing access to voluntary (as opposed to mandatory) confidential HIV testing and  
counseling; and addressing HIV-related stigma and discrimination. 
Health Consumer Powerhouse 
Euro HIV Index 2009 Report 
 
14 
 
Criminalization of HIV should be limited to cases of intentional transmission or 
exposure.  
In many countries, the EU healthcare consumer has the right to choose among providers 
of healthcare anywhere in their country. The exceptions to this are Finland, Poland, 
Portugal, and Spain, where patients are assigned to a specific district GP or specialist. In 
terms of choosing healthcare providers across borders, there are many barriers and no 
smooth mechanisms have been put in place to make it easier for patients who choose to 
be treated outside their national borders. Many national officials say that their citizens 
hardly ever take advantage of seeking care abroad and would prefer to be treated at home 
since HIV is a chronic disease requiring permanent care. If Europeans feel that the cross-
border option is not offered despite the decisions of the European Court of Justice, it is 
hardly surprising. Many countries also choose not to inform citizens that they can be 
treated in other EU countries.  
“The three ones” should be implemented by now in most countries; however we found 
that the situation is in general not good enough to have a real structure and strategy to 
efficiently fight again HIV.  Often the implementation has be done only partially and it is 
not working as expected. Countries like Hungary or Slovenia were hard to score because 
they have the three ones installed and operating, but there is still a room for improvement 
especially in the national Monitoring & Evaluation system. 
4.2  Sub discipline: Access 
National AIDS programmes and the international community have embraced the goal of 
universal access to HIV prevention, treatment, care and support by 2010. To achieve this 
goal, countries will need to address the obstacles blocking provision and uptake of 
prevention, treatment, care and support.  
The populations with higher HIV prevalence in Europe are:  men who have sex with men, 
IDU (injection drug users), and migrant populations originating from high prevalence 
countries, many of these migrant populations are undocumented migrants, asylum seekers 
and refugees. Language barriers, marginalization, social exclusion, and legal obstacles are 
the most common factors contributing to the HIV vulnerability of migrants.   
The indicator showing deployment of Anti-RetroViral (ARV) drugs per PLWH was ruled 
out because the quality of data on HIV prevalence was not good enough (See section 
7.7.1). 
As is shown in indicator 2.3 “Equal care for marginalized and migrant population”, 
several countries still do not provide the same access to migrants as to any other person 
living in the community with HIV. Lack of residence status and health insurance are the 
main factors that deprive migrants of HIV treatment and care. 
This issue is directly related to the number of undiagnosed patients (data not available) 
and late detection of HIV as is shown throw Indicator “2.6 % of patients starting ART 
at CD4 cell count < 200”, which would show the number of patients getting started on 
treatment too late. The analysis of the data brings two conclusions: data availability is not 
very good (most of the countries could not provide data) and there is a high share of 
Health Consumer Powerhouse 
Euro HIV Index 2009 Report 
 
15 
 
patients getting into treatment very late.  Doctors complain that many of these patients 
simply show up too late in their clinics. 
As HIV has become a chronic disease in Europe, it would be good if healthcare systems 
could provide patients with tools that will normalize their lives; Lipodystrophy surgery, 
alleviating side effects of ARV therapies, or sperm washing and other reproductive 
assistance, which allows couples to have a child in sero discordant couples reducing the 
risk of HIV transmission, should be of free access for everyone in need. This is actually 
not a common practice, as the services are provided in many countries only in the private 
sector, which means that most people would not able to reach them. 
There are several countries, particularly in CEE, where budgets used for HIV are either 
going to be reduced next year or were reduced already in 2009. This could bring terrible 
consequences. In countries like Czech Republic, where the institutions providing 
Voluntary and anonymous Counseling and Testing services (VCT) were reduced almost 
by half, restricting access to tests for people at risk. Additionally, cut-backs on personnel 
and material for testing and prevention will create surveillance problems.   
4.3  Sub-discipline: Prevention 
The free availability of PEP (Post-Exposure Prophylaxis) for health care personnel in 
case of accident with infected material is available everywhere. It is common however to 
find countries like Spain in which not every hospital can provide this service, which 
means that sometimes the person at risk would have to be transferred to another hospital 
to be treated.  
Free PEP provision in case of sexual, injection drug use or any other non-occupational 
exposure is less expanded and is normally provided only in case of rape or other kinds of 
sexual aggression. It is common to find that in those countries where PEP is offered for 
free, there is a tendency not to use it as often as would be recommended or at least as 
often as some people would consider reasonable.  
Sexual education is included in most of the school curriculums in Europe. However, the 
content of sexual education varies greatly within, as well as between, countries. In many 
cases, it is difficult to get a clear picture of what is included in each country. Also how 
this information is delivered varies a lot from country to country. In some countries 
sexual education is included as part of biology subject, in others it is part of religious 
education or social science. The topic is approached from very different perspectives in 
the different subjects.  
In general, the preparation and knowledge of teachers on this topic is very poor. So far, it 
seems sexual education in Europe has not been considered of great importance. There is 
strong international evidence that school-based sexuality education can be effective for 
reducing sexual risk behavior and is not associated with increased sexual activity or 
increased sexual risk taking, as some have feared1.  
                                                 
1
 Kirby D, Laris B and Rolleri L; 2005, 2006, 2007. 
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The HIV epidemic among Injecting drug users (IDUs) shows different developments in 
different parts of the European region. In general HIV infection rates are stable at low 
levels or in decline. It seems the efforts on harm reduction strategies put in place in most 
of the countries are working rather satisfactory. Additionally, the different approaches to 
improve testing and treatment of IDUs are helping to reduce further HIV transmission. 
Mother-to-child transmission is the primary route of HIV infection among children 
around the globe. Without intervention, an HIV-infected mother has more than 30 percent 
risk of passing the virus on to her baby during her pregnancy or birth, or via breast milk 
after the child is born. The increased prevalence of HIV infection in women is leading to 
a rising number of children born to HIV-infected mothers. As therapeutic possibilities for 
HIV/AIDS increase, the detection of undiagnosed HIV infections in pregnant women, 
followed by adequate management, is of crucial interest. Antenatal HIV screening 
policies are in place in most of the countries under study. In general a volunteer test is 
offered to every pregnant woman (either opt-in or opt-out) and only a few countries, like 
Denmark or Malta, make a selective screening in risk populations.  
Belgium, Greece, Italy, Hungary and Slovenia have not implemented a national screening 
policy. Belgium follows guidelines from their Association of Gynaecologists and 
Obstetricians who recommend antenatal HIV testing, provided that informed consent has 
been obtained. Finally Greece, Italy, Hungary, Slovenia have neither national policy nor 
professional guidelines with regard to antenatal HIV screening2. 
There are not many official guidelines or protocols suggesting or encouraging doctors to 
provide regular check-ups for STI or hepatitis to HIV patients. The result is that in 
every country and also between regions doctors do something differently and in many 
cases the patient is the one taking the initiative of getting tested.  
Sex workers do not account for much of the total HIV prevalence in Europe, only around 
2%. Needless to say, however, they account for a much higher proportion of multiple-
partner sexual acts, making them of the groups at risk to get infected and to transmit HIV. 
The original indicator selected to compare the situation of sex workers among European 
countries was excluded for lack of quantitative data.  The indicator was asking about 
provision of sex education to sex workers. Instead of that, Female condom sales and 
“Amnesty for prostitution” were included. The HCP believes that these two indicators 
will show indirectly some issues that can affect the situation of sex workers. 
Female condom use has been encouraged by different international organizations to 
improve women empowerment and to prevent STI. The female condom helps protect 
partners from pregnancy and sexually transmitted infections, including HIV. It is the only 
female-controlled device offering this protection. Globally there are several campaigns to 
distribute them in several countries in Africa and Asia. However, the HCP were very 
surprised to discover that although being encouraged in other parts of the world, there is 
almost no market for these condoms in Europe. Only one project in France has been 
established to distribute these condoms through sex workers and in dark rooms. The main 
                                                 
2
 Deblonde J et al; 2007. 
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distributor of female condoms would also not provide answers of why the product is not 
successful and why the use in this part of the world is so limited. 
Probably the programmes less developed, less coordinated and the area with the biggest 
lack of information are related with prisons. Some efforts have been done but still the 
reality of what happens in every prison is far from being updated or complete. In general, 
needle exchange programmes have not been established in most countries, even though 
some provide their prisoners with bleach to disinfect the needles, but that number is very 
limited. CEE countries need to make a big effort to implement substitution therapies in 
their prisons as those therapies are mainly not available, even though it has been 
demonstrated that they are a good way to reduce infections. Finally, almost half of the 
countries studied do not offer free distribution of condoms to their prisoners; highly 
recommended to prevent sexually transmitted infections.  As national prison authorities in 
one country remarked: “Condoms are handed out on request, but as condoms have a 
number of interesting areas of use outside of what the manufacturer intended, condoms 
are not ‘freely available’.” 
4.4  Sub-discipline: Outcomes  
There were two interesting indicators that could not be used due to lack of information. 
One is the number of undiagnosed HIV patients, data that is expected that do not exist, or 
only as estimation, the second is related with the survival of people living with HIV. 
The data presented under Deaths due to HIV/AIDS represent death due to AIDS as a 
first cause of death, not including those patients having AIDS, who died from any other 
collateral disease like cancer which is a significant cause of mortality and morbidity in 
people infected with HIV. This means the numbers for each country is underestimated.  
HIV prevalence in blood donations is in generally not a problem anymore. The blood 
from donors gets periodically tested and the protocols to follow this routine are perfectly 
optimized and standardized. 
There is evidence that co-infection of TB-HIV is growing and although there is a big 
effort for increasing the number of international initiatives to coordinate collaboration 
between TB and HIV communities, the data on % of TB patients tested for HIV could 
not be provided by many countries and only four (Belgium, Estonia, Latvia and Slovakia) 
test more than 80% of their TB patients for HIV. This makes it clear that further efforts 
need to be made to maximize access to existing effective interventions. 
In principle, if antenatal volunteer screening were efficient, not too many children would 
be infected by vertical transmission from their mothers.  The real situation is not that 
simple. Physicians complain that in many cases, especially for migrants, patients show up 
too late in the clinics. In many case mums find out about their HIV status being already 
pregnant. In several cases they get tested but frequently never pick up the results, and 
sometimes it is the first time they hear about their infection. Additionally, they do not 
always have access to the proper care and treatment.  
As was commented before, HIV/AIDS is a serious problem for prison populations across 
Europe. Prisons are extremely high-risk environments for HIV because of overcrowding, 
poor nutrition, limited access to health care, continued drug use and unsafe injecting 
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practices, unprotected sex and tattooing. However, the study could not find many 
countries in which transmission of HIV and HCV in prison is generally recorded. Policies 
for regular data collection are not always in place and it is difficult to monitor what is 
happening in each prison. In some countries still mandatory testing is taking place, 
especially among risk population. 
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4.5  Results in “Quadrathlon” – sub-discipline winners  
The EHIVI 2009 is made up of four sub-disciplines. As no country excels across all aspects of measuring a healthcare system, it can therefore be of interest to 
study how the 29 countries rank in each of the four parts of the “Quadrathlon”. The scores within each sub-discipline are summarized in the following table: 
 
As the table indicates, the total top position of Luxembourg healthcare system is to a great extent a product of good performance across the sub-disciplines, 
being in top position for Involvement and rights and Access but with some room to improve on Outcomes. 
Switzerland is in top position for Prevention, but has some difficulties to score on Access and Outcomes.  
Malta is the country that gets the highest score in Outcomes. It has been able to provide data to all indicators and has good results in HIV care. 
 
Sub-discipline Top country Score Maximum 
score 
1. Involvement and rights Luxembourg 190 200 
2. Access Luxembourg 227 250 
3. Prevention Switzerland 301 325 
4. Outcomes Malta 198 225 
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5.  How to interpret the Index results? 
The first and most important consideration on how to treat the results is with great care 
and caution against drastic conclusions. 
The Euro HIV Index 2009 is an attempt at measuring and ranking the performance of 
HIV care provision from a patient viewpoint. The results definitely contain information 
quality problems and several limitations. There is a shortage of pan-European, uniform 
set procedures for data gathering. 
The HCP finds it far better to present the results to the public, and to promote 
constructive discussion rather than staying with the only too common opinion that as long 
as healthcare information is not a hundred percent complete it should be kept in the 
closet. Again, it is important to stress that the Index displays patient information, not 
medically or individually sensitive data. 
While by no means claiming that the HIV Index results are dissertation quality, the 
findings should not be dismissed as random findings. Behind this report there are a high 
number of well know professionals working in the different fields of HIV as well as 
national representatives from all over Europe. This project is the result of months of 
research and discussions, and previous experience from the generalist Euro Health 
Consumer Indexes or Euro Diabetes Consumer Index. The HCP hopes that the HIV Index 
2009 results can serve as inspiration for how and where European HIV care can be 
improved. 
 
 
6.  European data availability on HIV care 
There is one predominant feature that characterizes European public healthcare (and other 
welfare states): there is an abundance of statistics on input of resources, but a traditional 
scarcity of data on quantitative or qualitative output.  
Healthcare systems operating more on an industrial basis have a natural inclination to 
focus monitoring on output, and much more naturally relate measurements of costs to 
output factors in order to measure productivity, cost-effectiveness, and quality. 
In the field of HIV, there are relatively many sources (compared with other diseases) for 
epidemiological data. There are internationally respected surveillance systems to monitor 
incidence and assess the impact of HIV. These systems have effectively informed policy 
and planning, and evaluation of interventions. Several prestigious organizations (WHO, 
ECDC, UNAIDS etc) publish data on new cases, trends of the disease by ages, trends by 
risk groups of the epidemic etc on a regular basis.  It could be hoped that with the number 
of cohort studies existing, together with the international collaborations like Eurosida, in 
general there would be no problems to find epidemiological data related to the disease. 
However, this study found several restrictions for obtaining data from these sources. 
There is a lack of data collection on indicators that reflect quality of treatment, clinical 
process or clinical outcomes. For example, when medical monitoring indicators were 
examined, it was found that indicators related with the status of CD4 or viral load in HIV 
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patients were either not properly collected or not collected at all. Even in spite of later 
improvement in mortality and morbidity in HIV-infected patients, general indicators such 
as control of HIV viral load and increase in CD4 cells over time may provide ways of 
measuring improvement of treatment strategies. 
Data on the frequency of visits to the doctor by patients (every 4 months, every six 
months…), the number of patients getting regular checkups for STI (like chlamydia) or 
data on pelvic examinations, tuberculosis (PPD screening) or hepatitis is in general not 
available. 
About medical care indicators; quality data is missing for most of the indicators related 
with access to treatment. For example, number of patients in need, receiving PCP 
prophylaxis (Pneumocystis Prophylaxis), or ARVs (Anti-RetroViral drugs).  
Some other very important data missing is a reliable number on HIV-infected individuals 
which at the moment is unknown in every country in Europe. The number of undetected 
cases is also not available, which is more understandable, even though there are some 
attempts to estimate these numbers. 
It is essential to be aware of the patient’s health status. It is also important to be aware of 
patient satisfaction and the degree of education that the patients have achieved in order to 
prevent further infections, and also to teach them how to manage their disease in a better 
way, especially nowadays that HIV/AIDS in Europe has become a long term, chronic 
disease.  Information about some of these topics can be found in the Eurosupport V 
which contributes to improve current strategies of secondary prevention, targeting PLHA 
and supporting them in adopting safer sex practices: To enhance informed decision-
making on fertility-related issues (e.g. family planning and pregnancy) among PLWH, to 
empower them to act accordingly and prevent unwanted consequences from sexual 
activity. 
Also interesting but not ready yet is: Stigma and discrimination Index. Such an Index 
could provide evidence for the success (or failures) of current programmes and highlight 
neglected areas requiring future action. These include improving workplace policies, 
informative debates about the criminalisation of HIV transmission, and promoting the 
realization of human rights. 
In the last years, the spreading of HIV/AIDS in prison has been one of the most urgent 
challenges to face in the fight against the infection. Needs of psychological, social, legal 
and medical support are only some of the problems that the penitentiary system has to 
face to guarantee the same level of assistance to inmates. However, it is rather 
disappointing that most data concerning the situation in prisons is not available. It just 
does not exist is not regularly collected. The project In and out is a very interesting 
report which is currently being updated. It records the situation in some European prisons 
and also some pilot projects. 
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7. Methodology: The Development of the HIV Index 
The Euro HIV Index 2009 is based on methodology developed during the work on the 
first three editions of the generalist Euro Health Consumer Index (EHCI). Therefore, the 
development history of that Index will be described below. 
7.1  Previous Euro Health Consumer Indexes 
7.1.1  Scope and content of the Euro Health Consumer Index 2005 
Countries included in the EHCI 2005 were Belgium, Estonia, France, Germany, Hungary, 
Italy, the Netherlands, Poland, Spain, Sweden, the United Kingdom, and, for comparison, 
Switzerland. To include all 25 member states right from the start would have been a very 
difficult task, particularly as many memberships were recent and would present dramatic 
methodological and statistic difficulties. The EHCI 2005 sought a representative sample 
of large and small and long-standing and recent EU membership states. One important 
conclusion from the work on EHCI 2005 was that it is indeed possible to construct and 
obtain data for an index comparing and ranking national healthcare systems seen from the 
consumer/patient’s viewpoint. 
7.1.2  Scope and content of EHCI 2006 – 2009  
The EHCI 2006 included all the 25 EU member states of that time and Switzerland using 
essentially the same methodology as in 2005. The number of indicators was also 
increased from 20 in the EHCI 2005 to 28 in the 2006 issue. The number of sub-
disciplines was kept at five. The “Customer Friendliness” sub-discipline was merged into 
“Patient Rights and Information”. The new sub-discipline “Generosity” (today Range and 
reach of services) was introduced because many observers, not the least healthcare 
politicians in countries having pronounced waiting-time problems, noted that absence of 
waiting-times could be a result of “meanness”. That is, national healthcare systems often 
restrict who gets certain operations so they appear to have less waiting list problems. In 
2008, the sub-discipline e-Health was introduced, and by 2009 Norway, Croatia, FYR 
Macedonia, Albania and Iceland has been included in the EHCI, covering 33 countries, 
with a special version also including Canada. 
To achieve a higher level of reliability of information, one essential work ingredient has 
been to establish a net of contacts directly with national healthcare authorities in a 
systematic way. The weaknesses in European healthcare statistics described in previous 
EHCI reports can only be offset by in-depth discussions with key personnel at a national 
healthcare authority level. 
7.1.3  Euro Consumer Heart Index 2008 
The first disease area-specific European HCP Index was the Euro Consumer Heart Index, 
published on July 3, 2008. It was deemed important to have a mix of indicators in 
different fields; areas of service attitude and customer orientation as well as indicators of 
a “hard facts” nature showing healthcare quality in outcome terms. It was also decided to 
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search for indicators on actual results in the form of outcomes and also indicators 
depicting procedures, such as “needle time” (time between patient arrival to an A&E 
department and thrombolytic injection), percentage of heart patients thrombolysed or 
given PCI, etcetera. 
Unlike previous HCP Indexes, the Heart Index contained indicators measuring public 
health status, such as total heart disease mortality. Also, under the Prevention sub-
discipline, the Heart Index went outside the scope of healthcare services by including 
factors such as smoking and diet. Such indicators tend to be primarily dependent on 
lifestyle or environmental factors rather than healthcare system performance, as general 
lifestyle factors are governed by so many other aspects of life.  
 
7.2  Euro HIV Index 2009 
The HIV Index is a compromise between which indicators were judged to be most 
significant for providing information about the different national healthcare systems from 
a patient’s/consumer’s viewpoint and the availability of data for these indicators. 
Therefore, it has been important to have a mix of indicators in different fields.  
It is important to understand that HIV is a very particular disease, not only because the 
nature of the disease itself (mortal until few years ago) but also because the social 
background behind it, as a high percentage of people living with HIV belong to marginal 
an stigmatised groups such as IDU (injection drug users), sex workers, prisoners or 
migrants.   
It is important to notice that in the index we wanted to bring an overview not only from 
every country included in the study but also from the groups were prevalence of HIV are 
higher and in which more actions must be taken. 
Some years ago AIDS was a deadly disease. However, today with good care it has 
become a chronic disease. The way PLWH live their disease is also different from any 
other chronic disease because of the frequent episodes of stigma and discrimination. 
The implication and dedication of the professionals working in this field are not like in 
any other medical speciality and the same can be said about the NGOs and patient 
organizations.  
In this index it is relevant to highlight some of the indicators included, e.g. those related 
to discrimination and stigma in different backgrounds (schools, housing or refusal from 
non-HIV-clinics), also important is the indicator about criminalization of HIV, a topic 
that is currently under debate in Europe, trying to find the best way to judge those cases of 
exposure or transmission of HIV.  
Furthermore, as a reflex of the lack of leadership in Europe the following indicators are of 
high relevance: 
- The three Ones 
- Sexual education on the curriculum of compulsory school  
- Do marginalized and migrant people receive equal health care and treatment?  
- % of patients initiating cART at a CD4 count < 200 
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- % of TB patients tested for HIV  
 
7.2.1 Sub-disciplines chosen for the HIV Index 2009 
Experience from the consecutive annual Euro Health Consumer Index editions, and from 
the Euro Consumer Heart Index, has been evaluated and applied when designing the HIV 
Index. After thorough discussions at several meetings with an expert reference panel, it 
was decided to divide the HIV Index into four sub-disciplines: 
 
Sub-discipline Number of indicators 
Involvement and rights 7 
Access 6 
Prevention 9 
Outcomes 6 
 
The weight of a sub-discipline is entirely independent of the number of indicators under 
each sub-discipline: the weight is given only by the applied weight coefficient. However, 
the effect of having a high number of indicators in a sub-discipline does reduce the 
relative weight of each single indicator in the final total score (see Table in Section 7.2.4). 
7.2.2  Scoring in the HIV Index 2009 
The performance of national healthcare systems was graded on a three-grade scale for 
each indicator, where the grades have the rather obvious meaning of green = good (i), 
amber = so-so (l), and red = not-so-good (h). A green score earns 3 points, an amber 
score 2 points, and a red score (or a “not available”) 1 point. 
For each of the four sub-disciplines, the country score was calculated as a percentage of 
the maximum possible score.  
Thereafter, the sub-discipline scores were multiplied by the weight coefficients given in 
the following section and added to make the total country score. The scores thus obtained 
were multiplied by (1000/the sum of weights; see Section 5.2.1) and rounded to a three 
digit integer, giving a score system where a state with “all Green” would receive 1000 
points (and “all Red” 333 points). 
One (minor) reason for this somewhat complex scoring methodology has been driven by 
reducing the likelihood of two or more states ending up in a tied position.  
7.2.3  Threshold value settings 
There has not been in general an ambition to establish a global, scientifically based 
principle for threshold values to score Green, Amber, or Red on the different indicators.  
Some of the indicators are score following international guide lines, scientific articles, 
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and other experts opinions. If those criteria were not found (after asking and looking 
deeply) or not established, threshold levels have been set after studying the actual 
parameter value spreads in order to avoid having indicators showing “all Green” or 
“totally Red”. For example, it is well known that in every country under study examples 
of discrimination could be found, so in principle every country could get a Red for this 
indicator. However, in some countries it is happening more often and is more widespread 
than in others; those are the countries getting a Red score. 
Setting threshold values for indicators where the data are numerical values is typically 
done by studying a bar graph of country data values on an indicator sorted in ascending 
order. This approach usually produces an S-shaped curve that is studied for notches in the 
curve, which can distinguish clusters of states. These notches are often taken as cut-off 
values for scores. A slight preference is also given to threshold values with even numbers.  
Finally, the HCP is a value-driven organisation. We believe in Patient/Consumer 
Empowerment, an approach that places highest importance on quantitative and qualitative 
healthcare services.  
 
7.2.4  Weight coefficients 
The weighting mechanism used to determine the relative weights of the sub-disciplines 
was originally introduced for the HCP Euro Health Consumer Index 2006. Explicit 
weight coefficients for the four sub-disciplines were introduced after careful 
consideration and discussion with the expert reference panel on which sub-disciplines 
should be considered for higher weight.  
In the HIV Index, the Prevention sub-discipline was the main candidate for a high weight 
coefficient based not only on the discussion with the expert reference panel but it is well 
known in the field that a good prevention programmes, reaching all the groups at risk, 
brings good outcomes. 
Access was chosen as the second most important sub-discipline, because of the 
importance of having access to care and to treatment in order to control the epidemic.  
After evaluating the data availability and quality, Outcomes were considered the third 
most important sub-discipline. It would be perfect to have an indicator reflecting death by 
HIV not only as a primary (initial) cause of death but as a contributing (secondary) cause. 
Also very interesting would be to have data for “Risk of HIV and HCV transmission in 
prison” or “% of patients on ART with viral load not detectable”, mostly not available. 
Involvement and rights end up having the lowest weight even though two indicators in 
that sub-discipline were awarded a high specific weight due to their relevance, those are 
criminalization of HIV and “The three ones”. 
In the HIV Index, a weighting novelty has been introduced in the form of different 
weights for individual indicators in three levels, Low, Medium or High. The relative 
weights of L/M/H have been set as 1/2/3, which simply means that a Green for a Low 
weight indicator gives 3 points, for a Medium weight Indicator 6 points and for a High 
weight indicator 9 points. For all indicators, an Amber score gives 2/3 of a Green score, 
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and a Red gives 1/3. Low/Medium/High weights are indicated in the final score matrix 
(Section 3) by small, medium size and large circle symbols respectively. 
This means that for prevention, the score for a country has been calculated as percent of 
the maximum: 9 x (3 x individual weight for each indicator) = 54. 
In the HIV Index 2009, the scores for the four sub-disciplines were given the following 
weights: 
Sub-discipline 
Relative 
weight 
Points for a Low 
weight Green 
score in each 
sub-discipline 
towards the total 
1000 
Points for a 
Medium weight 
Green score in 
each sub-
discipline 
towards the total 
1000 
Points for a High 
weight Green 
score in each sub-
discipline towards 
the total 1000 
Involvements and rights 200 14.29 28.57 42.86 
Access 250 22.72 45.45 68.18 
Prevention 325 18.06 36.11 54.16 
Outcomes 225 16.07 32.14 48.21 
Total sum of weights 1000    
 
Consequently, as the percentages of full scores were added and multiplied by (1000/Total 
sum of weights), the maximum theoretical score attainable for a national healthcare 
system in the Index is 1000, and the lowest possible score is 333. 
It should be noted, as there are not many examples of countries that excel in one sub-
discipline but do very poorly in others, that the final ranking of countries presented by the 
HIV Index 2009 is remarkably stable if the weight coefficients are varied within 
reasonable limits. The four countries making up the top group in the Index results remain 
the same also if weights are varied within quite wide limits. It is, of course, possible to 
create subtle differences in the internal order of countries placed close together (see 
Section 6.1) by changing the weights, but such subtle differences should not be the basis 
for any detailed conclusions. 
The project has been testing other sets of scores for Green, Amber, and Red, such as 2, 1, 
and 0 (which would really punish low performers), and also 4, 2, and 1 (which would 
reward real excellence). The final ranking is remarkably stable also during these 
experiments. In addition, it would probably be grossly unfair to countries scoring red to 
give that score the numerical value of 0. In 2009, the standards of HIV care in Europe, 
also in states scoring low in the Index, are not so low that a score of 0 would be 
appropriate. 
7.2.5  Regional differences within European states 
The Health Consumer Powerhouse is well aware that many European states have very 
decentralised healthcare systems. Not least for the U.K., it is often argued that “Scotland 
and Wales have separate HNS services, and should be ranked separately”. The uniformity 
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among different parts of the U.K. is probably higher than among regions of Spain, Italy, 
or Germany;  
As equity in healthcare has traditionally been high on the agenda in European states, it has 
been judged that regional differences are small enough to make relevant and meaningful 
statements about the national levels of healthcare services. 
7.3  “CUTS” data sources 
Whenever possible, research on data for individual indicators has endeavoured to find a 
“CUTS” (Comprehensive Uniform Trustworthy Source). If data on the underlying 
parameter behind an indicator is available for all or most of the 29 states from one single 
and reasonably reliable source, then there has been a definitive preference to base the 
scores on the CUTS. As CUTS would be considered data, WHO databases, OECD Health 
data, EuroHIV, Eurostat , and scientific papers using well-defined and established 
methodology. 
Apart from the sheer effectiveness of the approach, the basic reason for the concentration 
on CUTS, when available, is that data collection primarily based on information obtained 
from 29 national sources, even if those sources are official Ministry of Health or National 
Health/Statistics agencies, generally has high noise levels. It is notoriously difficult to 
obtain precise answers from many sources even when these sources are all answering the 
same question. For example, it has been difficult to find answers to indicators like “Do 
marginalized and migrant people receive equal health care and treatment??” or “Access to 
free drug resistance testing in failing patients? The law established or the guidelines 
approved are very different from what happened in reality.  
Some indicators had to be excluded, as under the same question people were answering 
very different things or because they were impossible to quantify; e.g.“Voluntary and 
anonymous testing service (VCT)”. Under the same question there are several alternative 
interpretations such as Do you have enough?, Are the tests effective?, Which proportion 
of people in need has access to it?  
It has to be emphasized that also when a CUTS for an indicator has been identified, the 
data are still checked through procedures described in Section 7.6, as there have 
frequently been occasions where national sources or scientific papers have been able to 
supply more recent and/or higher precision data. 
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7.4   Indicator definitions and data sources for the Euro HIV Index 2009  
A more extensive description of the precise questions behind the indicators is found in section 7.6. 
Sub- 
discipline Indicator 
Explanatory 
comment 
i 
Score 3 
l 
Score 2 
h 
Score 1 
Main Information 
Sources 
1. 
Involvement 
and rights 
1.1 Discrimination of people 
with HIV 
a) General b) Housing c) 
Employment d) Schools. 
No, this would be a 
minimal problem 
Not frequently, but 
it does happen. 
Yes, definitely. Patient survey commissioned by Health 
Consumer Powerhouse from Patient View 
2009. Personal interviews with experts 
and health care officials. 
1.2 School attendance for 
children with HIV? 
  Yes, to all schools 
by law 
There is law but 
children still get 
rejected. Or 
children receive 
mandatory 
checkups before 
entering the school  
There is no law 
that forces schools 
to accept all kids.  
Personal interviews with experts and 
health care officials. 
1.3 Criminalisation of HIV (NB! Three sub-scores!) Is there 
an HIV specific law? NO=3, 
Yes=1; Is exposure to HIV 
prosecutable? NO=3, Yes=1; Is 
transmission of HIV 
prosecutable? Yes=3,No=2 
      Terrence Higgins Trust Survey 
http://www.gnpplus.net/criminalisation/ind
ex.php?option=com_content&task=view&i
d=21&Itemid=42 
1.4 Refusal of treatment 
from non-HIV-doctors 
  No, this would be a 
minimal problem 
Not frequently, but 
it does happen. 
Yes. definitely Patient survey commissioned by Health 
Consumer Powerhouse from Patient View 
2009. Personal interviews with experts 
and health care officials. 
1.5 Right to choose 
HIV/AIDS care in another EU 
state 
Can patients freely choose non-
acute HIV care in another 
country? 
Yes Yes, with pre-
approval, but 
usually no problem  
No, or yes with 
pre-approval, but 
usually problems 
or time delays  
Patient survey commissioned by Health 
Consumer Powerhouse from Patient View 
2009. Personal interviews with experts 
and health care officials. 
1.6 National organization for 
"people living with HIV"? 
Not only taking care of HIV 
political related issues or 
prevention issues 
Yes, at least one Only regional No Personal interviews with experts and 
health care officials. 
1.7 The three ones:  1 national policy, 1 central 
responsible body, 1 testing and 
reporting system 
The country has 
the three ones 
The country has 
only two of them 
established 
Only one or none UNGASS - National Composite Policy 
Index (NCPI) 2007 and Personal 
interviews with experts and health care 
officials. 
2. Access 
2.1 Free drug resistance 
testing 
Before initiation Yes Yes, but the access 
is limited (finance 
issues, not free 
access for 
marginalized people 
etc.) 
No Personal interviews with experts and 
health care officials. 
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Sub- 
discipline Indicator 
Explanatory 
comment 
i 
Score 3 
l 
Score 2 
h 
Score 1 
Main Information 
Sources 
2.2 Free drug resistance 
testing in failing patients 
  Yes Yes, but the access 
is limited (finance 
issues, not free 
access for 
marginalized people 
etc.) 
No Personal interviews with experts and 
health care officials. 
2.3 Equal care for 
marginalized and migrant 
population 
Undocumented migrants, 
marginalized people and 
uninsured individuals;  
equivalent to that available to 
people living in the community 
with HIV) 
Yes, all have 
unrestricted free 
access to health 
care. 
Migrants with no 
health insurance can 
get special temporary 
status or are partially 
covered (sometimes 
through no well 
defined "necessary or 
urgent" medical care) 
(sometimes through 
NGOs) 
Only those with 
health insurance  
/or national social 
security have 
access. 
Personal interviews with experts and 
health care officials and 
http://www.cdprg.org/Docs/bn_hivtesting.
pdf and PICUM reports 
2.4 Access to lipodystrophy 
treatment? 
Access to the treatment Yes, it is free Only private or 
partially paid by the 
patient 
Not available Patient survey commissioned by Health 
Consumer Powerhouse from Patient View 
2009. Personal interviews with experts 
and health care officials. 
2.5 Reproductive assistance 
available 
(sperm washing etc.) Yes, it is free Only private or 
partially paid by the 
patient 
Not available Personal interviews with experts and 
health care officials. 
2.6 % of patients starting 
ART at CD4 cell count < 200 
Late diagnosed patients. 0-30% 30-50% More than 50% Personal interviews with experts and 
health care officials. 
3. 
Prevention 
3.1 Availability of PEP  Post-Exposure-Prophylaxis: Is 
access free for health care staff 
and non occupational 
Exposure? 
Yes available for 
free to everyone in 
need, no 
limitations. 
Available to everyone 
but you have to pay 
for "non-occupational  
exposure", some 
accessibility 
problems, only 
available under 
certain 
circumstances 
Not available or 
only available for 
heath care staff 
Personal interviews with experts and 
health care officials. 
3.2 Harm reduction for drug 
users 
HIV infections newly diagnosed 
in injecting drug users per 
million population (2006) 
< 5 (5-20) > 20 EuroHIV  
3.3 Pregnant women 
counseled and tested for 
HIV. 
  Universal 
screening, 
voluntary testing, 
opting in 
Universal screening, 
voluntary testing, 
opting out or 
Selective screening, 
voluntary testing, 
opting in 
No national 
screening policy 
http://eurpub.oxfordjournals.org/cgi/reprint
/ckm074v1 
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Sub- 
discipline Indicator 
Explanatory 
comment 
i 
Score 3 
l 
Score 2 
h 
Score 1 
Main Information 
Sources 
3.4 Rapid test availability At care point Yes, available for 
free in most care 
points 
Rapid testing has not 
yet been introduced 
within health care 
sector or not for free, 
or only in very few 
care points. 
Not available  Personal interviews with experts and 
health care officials. 
3.5 Female condom sales Female condom sales 2007-
2008 per 100 000 population 
> 200 Units  < 200 Units None Female Health Company 
3.6 "Amnesty" for 
prostitution 
  Prostitution legal 
and regulated 
according to best 
practice  
Prostitution legal but 
is not regulated / 
unclear or non/best 
practice regulations. 
but organized 
activities such as 
brothels and pimping 
are illegal;  
Prostitution illegal Personal interviews with experts and 
health care officials. 
3.7 Harm reduction in 
prison  
 Needle exchange programme; 
Free available condom 
distribution;  Substitution 
therapies (OST) Antagonist or 
agonist ; Bleach 
All Prisons  Half of prisons No WHO Prison health data base 
3.8 Sexual education in 
compulsory school  
On the curriculum Mandatory Not mandatory but 
often given 
infrequently The SAFE project 
3.9 HIV patients screened 
for STI and hepatitis 
Annual screening At least once a 
year 
Only if the person 
themselves takes 
the initiative to 
have a test, not in 
regular basis 
(sometimes) 
People with HIV do 
not get screened 
for STIs and 
hepatitis 
Patient survey commissioned by Health 
Consumer Powerhouse / From Patient 
view 2009. Personal interviews with 
experts and health care officials. 
4. 
Outcomes 
4.1 % of TB patients tested 
for HIV 
% of all Tb patients from whom 
HIV test results was known 
(WHO) 2007 
> 80% 80-20% < 20% http://www.who.int/globalatlas/predefinedr
eports/tb/index.asp?strSelectedCountry=
GBR 
4.2 Deaths due to HIV  Death due to AIDS standarized 
death rate by 100.000 
inhabitants 
0-0,5 > 0,5-1 > 1 Eurostat 2007 ;  
http://epp.eurostat.ec.europa.eu/tgm/table
.do?tab=table&init=1&language=en&pcod
e=tps00143&plugin=0 
4.3 HIV prevalence in blood 
donations  
HIV Prevalence in blood 
donations  per 100.000 
donations (first-time or 
candidate donors included). 
Data 2006 
< 1  (1-4) > 4 HIV/AIDS Surveillance in Europe    
http://www.eurohiv.org/reports/report_76/
pdf/report_eurohiv_76.pdf 
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Sub- 
discipline Indicator 
Explanatory 
comment 
i 
Score 3 
l 
Score 2 
h 
Score 1 
Main Information 
Sources 
4.4 Prevention MTCT HIV infections newly diagnosed 
in persons infected through 
mother-to-child transmission per 
100.000 live births (2006) 
< 1 1 - 5 > 5 http://www.eurohiv.org/reports/report_75/
pdf/report_eurohiv_75.pdf    (data 2006) 
4.5 Risk of HIV and HCV 
transmission in prison 
Subject to present regulations HIV and HCV 
volunteer testing at 
admission an 
before release  
HIV and HCV 
volunteer testing at 
admission but not 
test performed 
before release 
Test are 
mandatory or they 
performed only HIV 
test or they do not 
performed any 
tests 
WHO health in prison; In and Out report; 
interview with health officials 
4.6 % of patients on ART 
with viral load not 
detectable 
  > 80% 80-60% < 60% Personal interviews with experts and 
health care officials. 
 
Table 7.4: Indicator definitions and data sources for the Euro HIV Index 2009
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7.4.1  Additional data gathering/evaluation - survey 
In addition to public sources, as has been the practice for all editions of Euro Health 
Indexes, an e-mail survey to Patient organisations and individual patients was 
commissioned from Patient View (Woodhouse Place, Upper Woodhouse, Knighton, Powys, 
LD7 1NG, Wales, Tel: 0044-(0)1547-520-965; info@patient-view.com). This year for the Euro 
HIV Index the HCP has had had the collaboration of AAE (Aids Action Europe) and 
EATG (European Aids treatment group) helping Patient View with the distribution of the 
survey among their branches to raise the response rate to the survey. 
The survey covered indicators in: involvements and rights, access and procedures. The 
survey was designed with the intention to improve information mainly on stigma and 
discrimination issues.  A total of 834 responses were obtained on this survey. The results 
of the survey have been used mainly to assess the “real situation” regarding some of the 
indicators. On no indicator the survey has been awarded CUTS status. 
7.4.2 Additional data gathering – feedback from National Ministries /Agencies and 
particularly national HIV experts 
In the first half of July 2009, the individual country preliminary score sheets were sent out 
to several parties where contact had been established such as the respective Ministries of 
Health and /or national agencies, NGOs and especially HIV experts and their respective 
professional associations of all 29 countries, giving the opportunity to supply more recent 
data and/or higher quality data than what is available in the public domain. 
Gathering data took place primarily throughout February, March, April, and May 2009 in 
personal meetings, telephone meetings, and extensive e-mail exchanges with officials at 
national Ministries of Health and/or health agencies and HIV experts. Feedback responses 
were provided by the countries presented in the table below. The table shows which 
countries returned an actual updated score sheet with comments. In addition to these score 
sheets, feedback was provided in several ways, both written and oral, from 24 of the 
countries. 
Country 
Responded in 
forms of feedback 
on the preliminary 
score sheet in 2009 Country 
Responded in 
forms of feedback 
on the preliminary 
score sheet in 2009 
Austria √ Lithuania √ 
Belgium √ Luxembourg √ 
Bulgaria √ Malta √ 
Cyprus √ Netherlands  
Czech Republic √ Norway  
Denmark √ Poland √ 
Estonia √ Portugal √ 
Finland 
 
Romania 
 
France 
 
Slovakia √ 
Germany √ Slovenia √ 
Greece √ Spain √ 
Hungary √ Sweden √ 
Ireland √ Switzerland √ 
Italy √ United Kingdom √ 
Latvia √   
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Corrections were accepted only in the form of actual data, evidence, or background 
information and not by merely changing a score. Surprisingly, honesty often prevailed and 
scores were sometimes revised downwards after reconsideration of the scores on the 
individual country’s preliminary score sheets. 
7.5   Symmetry of in-data 
It is important to note that there is absolutely no symmetry in the data used for the scores 
in the HIV Index. The project has consistently been using “latest available” statistics; this 
means that in some indicators data from 2005 from one country was compare with data 
from another country from 2007. In accordance with the HCP mission to drive active 
quantitative and qualitative monitoring of healthcare services, this is in the HCP Index 
projects and is considered a problem in countries not monitoring/reporting rather than a 
HCP problem.  
For many indicators, perhaps most notably the “Availability of PEP (post-Exposure-
Prophylaxis) or % of patients starting ART at CD4 cell count < 200”, in the Euro HIV 
Index, data from several sources have been piled on top of each other in order to obtain 
what could be considered the least inaccurate picture of the real situation.  
HCP has also allowed itself to test official policy decisions in a patient survey and by 
interviews with healthcare officials. In some cases, where real life practice does not seem 
to coincide with official policy decisions, scores have been modified accordingly. This 
happened especially in indicators like “the 3 ones” or Equal care for marginalized and 
migrant people equivalent to that available to people living in the community with HIV? 
7.6  Content of indicators in the Euro HIV Index 2009 
The aim has been to select a limited number of indicators, within a definite number of 
evaluation areas, which taken together can shows the health care provision to patients and 
the prevention programmes on going in the respective countries. 
To make sure that the indicators were well defined and comparable among countries, after 
the first meeting with the Expert Reference Panel (December 2008), further discussions 
with HIV prevention quality assurance experts were taking place, as well as with civil 
society organizations, experts in health in prisons, experts in tuberculosis, experts in 
health care policies for migrants and HIV criminalization. 
The above mentioned four sub-disciplines (Section 4.1) were selected to describe 
important aspects of HIV care. In the following pages, each indicator, with the actual 
indicator question asked, is briefly described. 
On indicators where scores are based on “CUTS” (Comprehensive Uniform Trustworthy 
Source), this is noted under each indicator bullet.  
“Interviews with national HIV or infectious diseases Experts and healthcare officials” 
normally means that HCP staff had been paying personal visits to Ministries of Health 
and/or National Health Agencies, National Statistical Agencies, and individual HIV 
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experts or NGOs working in the field. The usual meeting form has been a two-hour 
sitting with groups of 2 -10 people.  In some cases, these contacts have been conducted 
over the telephone. These meetings have also served as preparation for the “preliminary 
score sheet send out” (Section 7.9.3.2). 
7.6.1  Involvements and rights 
1.1 Do people living with HIV and aids frequently face discrimination?  
The first approach to answer this indicator was to ask patient organizations and 
national bodies, but in many cases there were high discrepancies between what 
national bodies said and what the patients said. Only few countries had performed 
their own surveys to assess the situation. For this reason one question in the Patient 
View survey was included to examine whether rejection by family, friends, health 
care personnel , workplaces or schools is common (please see patient survey 
Appendix 1). Non-CUTS data. 
 
1.2 School attendance for children with HIV 
 
1.3 Criminalization of HIV  
After a long debate of what would be the best to measure under this indicator and 
which criteria should be used, it was agreed that the best way (with its limitations and 
taken into consideration the data available) would be to measure three different 
things:  
1. Is there an HIV specific law? All countries that do not have an HIV-specific law 
to take care of issues related to HIV among other infectious diseases. UNAIDS 
encourages avoiding to introduce HIV-specific laws and instead to apply general 
criminal law to cases of intentional HIV transmission.  
2. Is exposure to HIV prosecutable? Countries in which exposure is not prosecutable 
would get high scores, considering that in many cases this exposure is not 
intentional. The assumption is that on this point a good education would be more 
useful that a sentence. 
3. Is transmission of HIV prosecutable? Following the same criteria be said the same 
that on the previous point. However, to actually infect another person with HIV 
should have more consequences than exposure to HIV. This is why countries 
where transmission may be prosecutable will score high, and countries that do not 
would get low score. 
It would be important and more accurate to know if countries make a distinction between 
exposure and transmission when the act has been intentional or non intentional.   
The data was acquired from Terence Higgins Trust, which collected data on 
criminalization in Europe. CUTS data. 
1.4 Frequency of refusal of treatment from non-HIV-doctors. As part of the stigma 
and discrimination suffered by PLWH, patients often face rejection from medical 
professionals from non- HIV clinics; such as dentists and surgeons. The data was 
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acquired from interviews with health officials, members of NGOs and the Patient 
Survey commissioned by Health Consumer Powerhouse from Patient View 2009. 
Non-CUTS data. 
1.5 Do HIV/AIDS patients have the right to choose among EU providers. Patients 
should have the right to choose healthcare providers in neighboring countries, as was 
recently confirmed by the European Commission. PLWH frequently suffer from other 
diseases like cancer or tuberculosis in which this kind of access would improve their 
care. The data was acquired from interviews with health officials and Patient Survey 
commissioned by Health Consumer Powerhouse From Patient View 2009. Non-
CUTS data. 
1.6 National organization for "people living with HIV”. The data was acquired from 
interviews with health officials and national bodies. Non-CUTS data. 
1.7 “The three ones” principle was defined in April 2004 after a meeting co-hosted 
by the United Kingdom and the United States. The idea was to ensure the most 
effective and efficient use of resources, and to ensure rapid action and results-based 
management:  
• One agreed HIV/AIDS Action Framework that provides the basis for 
coordinating the work of all partners.  
• One National AIDS Coordinating Authority, with a broad multisectoral 
mandate.  
• One agreed country-level Monitoring and Evaluation System.  
The data was acquired from interviews with health officials and national bodies and 
review by members of NGOs. Non-CUTS data. 
7.6.2  Indicators for Access 
The sub-discipline measures the access for patients to their health care systems, with 
special attention to marginal people and all kinds of migrants. 
2.1 Access to free drug resistance testing? Before initiation:   HIV is "resistant" to a 
drug if it keeps multiplying rapidly while the patient is taking the drug. Changes 
(mutations) in the virus cause resistance. HIV mutates almost every time a new copy 
is made. Not every mutation causes resistance. The "wild type" virus is the most 
common form of HIV. Anything different from the wild type is considered a 
mutation. An antiretroviral drug (ARV) will not control a virus that is resistant to it; it 
can "escape" from the drug. Resistance testing helps health care providers make better 
treatment decisions for patients. Data was acquired from interviews with health 
officials and national bodies, review by NGOs. Non-CUTS data. 
2.2 Access to free drug resistance testing in failing patients. Data was acquired from 
interviews with health officials and national bodies.  Non-CUTS data. 
2.3 Do marginalized and migrant people receive equal health care and treatment? 
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In July 2005, leaders of the Group of Eight (G8) countries announced their intention 
to “work… with WHO, UNAIDS and other international bodies to develop and 
implement a package for HIV prevention, treatment care, with the aim of as close as 
possible to universal access to treatment for all those who need it by 2010”.  
This indicator summarises the findings of access to HIV prevention, treatment and 
care among migrants and marginalized groups of people in the EU.  
Nowadays, still in several countries access to care for marginal and migrants can be 
very difficult. Data comes from interviews with patients’ associations and healthcare 
officials but also interviews and different documentation published by PUCUM and 
“AIDS and mobility”. Non-CUTS data.  
2.4 Access to lipodystrophy treatment. 
Like most medicines, antiretroviral drugs can cause side effects. Lipodystrophy is one 
of them. It is a medical condition characterized by abnormal or degenerative 
conditions of the body's adipose tissue. A more specific term, lipoatrophy is used 
when describing the loss of fat from one area (usually the face). Data was acquired 
from interviews with health officials and Patient Survey commissioned by Health 
Consumer Powerhouse from Patient View 2009. Non-CUTS data. 
2.5 Reproductive assistance (sperm washing etc.) available: People living with HIV 
may require reproductive counselling and assistance in order to limit the risk of sexual 
or vertical transmission, or to overcome an infertility problem. Reproductive 
treatments exist for both HIV-positive men and women, and their efficacy has been 
largely proven. Data was acquired from interviews with health officials and national 
bodies. Non-CUTS data. 
2.6 % of patients starting ART at CD4 cell count < 200: This indicator measures the 
number of patient getting treatment as early as should be. Data was acquired from 
interviews with health officials and national bodies and some Cohort studies. Non-
CUTS data. 
7.6.3  Indicators for Prevention 
3.1 Availability of PEP (post-Exposure-Prophylaxis):  PEP is what the name 
suggests; prophylaxis (preventative) medications given after an HIV or suspected HIV 
exposure in the hope of decreasing the likelihood of HIV infection from the exposure. 
The provision of antiretroviral drugs might be beneficial to prevent HIV infection not 
only after occupational exposure but after unanticipated sexual or injection drug use 
exposure. The access and availability of these drugs differ a lot from country to 
country. Data was acquired from interviews with health officials and national bodies. 
Non-CUTS data. 
3.2 Harm reduction for drug users.  Injecting drug users (IDUs), and blood transfer 
through the sharing of drug taking equipment, particularly infected needles, is an 
extremely effective way of transmitting HIV. HIV epidemics among IDUs show 
different developments in different parts of the European region. In every country 
several programmes to reduce harm reduction in IDU are implemented. However, to 
measure the efficiency of programmes established and the amount of people reached 
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by those programmes is difficult to know, it was agreed that a good indicator that 
could show the quality of the programmes would be to measure the numbers of HIV 
infections newly diagnosed in injecting drug users per million population. Data has 
been obtained from EuroHIV report 2006. CUTS data. 
 
3.3 Pregnant women counselled and tested for HIV. The increased prevalence of 
HIV infection in women is leading to a rising number of children born to HIV-
infected mothers. Testing and counselling are interventions needed for the prevention 
of MTCT of HIV. In this indicator was recorded the National policies and strategies 
with regard to antenatal HIV screening. The data was acquired from the article 
“Antenatal HIV screening in Europe: a review of policies3 )and completed with 
interviews with health officials and national bodies. Non-CUTS data. 
3.4 Rapid test availability. Typically, the test requires two visits; one to receive pre-
test counselling and have your blood drawn, and the second to receive HIV testing 
results, post-test counselling and medical referrals for HIV care if the results are 
positive. Rapid HIV testing makes it possible for the patient to get pre-test and post-
test counselling, test results and any medical referrals they may need all in one visit 
and in a very short time. Data was acquired from interviews with health officials and 
national bodies. Non-CUTS data. 
3.5 Female condom sales. The female condom was first made from polyurethane. 
This version is officially called the "FC Female Condom". A newer version is made of 
nitrile rubber and called "FC2" (this material change was announced in September 
2005). The newer nitrile condoms are less likely to make potentially distracting 
crinkling noises. WHO and UNAIDS are encouraging wider access to the female 
condom as a method of preventing both pregnancy and sexually transmitted 
infections. Many governments and non-governmental organisations provide female 
condoms for free or at subsidised prices as part of their HIV prevention and family 
planning programmes. A study in 2006 found that countrywide distribution 
(equivalent to 10% of condom sales) of the FC2 female condom in Brazil and South 
Africa would be “useful and cost-effective” for preventing HIV (Dowdy DW et al; 
2006). 
3.6 “Amnesty” for prostitution. It has been demonstrated in different settings that 
legalization of prostitution reduces risk for prostitutes and improves their health 
conditions. The indicator was introduced to record the political situation of 
prostitution in the countries included in the study, and their accessibility to health 
care. The data was acquired from interviews with health officials and national bodies 
and we used different documentation publish by Tamped as well as local NGOs. Non-
CUTS data. 
3.7 Harm reduction in prison. Prevalence of HIV infection among prisoners in many 
countries is significantly higher than in the general population. Hepatitis C virus 
prevalence is even higher. Though most prisoners living with HIV contract their 
infection prior to imprisonment, the risk of being infected in prison, specifically 
                                                 
3
 Deblonde et al; 2007 
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through the sharing of contaminated injecting equipment, is high. This indicator wants 
to show the strategies set up in the countries to reduce and prevent these infections. It 
measures a) Free available condom distribution in prison, b) needle exchange 
programmes, c) availability of Substitution therapies (OST) Antagonist or agonist and 
d) the provision of disinfectants ("bleach") that can be used for cleaning of syringes 
available.  The data was acquired from the health in prison project (WHO) and 
completed and review through interviews with health officials and national bodies and 
some data are coming from “In and out” project. Non-CUTS data. 
 3.8 Sex education on the curriculum of compulsory school. Sexual education 
enables young people to make informed choices about sexual relationships and to 
protect their sexual health.  There is strong international evidence that school-based 
sexuality education can be effective in reducing sexual risk behaviour and is not 
associated with increased sexual activity or increased sexual risk taking. The data was 
obtained from “The SAFE project” and review by health officials and national bodies.  
CUTS data 
3.9 HIV patients screened for STI and hepatitis annually: In general there is a 
consensus about the relevance of carrying out STI and hepatitis test in HIV patients 
annually. Data was acquired from interviews with health officials and Patient Survey 
commissioned by Health Consumer Powerhouse from Patient View 2009. Non-CUTS 
data. 
7.6.4  Indicators on Outcomes 
Treatment and management of chronic illness is an increasing concern as costs of medical 
care rise and the number of persons with chronic illnesses grows. A better understanding 
of the effectiveness and costs of interventions designed to improve patient control over 
chronic conditions is needed. 
4.1 % of TB patients tested for HIV: % of all TB patients from whom HIV test 
results are known. The risk of tuberculosis is greater in HIV patients than in the 
majority of the population as can be seen from numerous research projects. The need 
for systematic testing for HIV infection in all tuberculosis patients by undertaking 
confidential HIV tests on admission to a tuberculosis programme is brought out. This 
measure would increase the number of cases diagnosed and provide data for better 
surveillance of the co-infection. Worldwide, tuberculosis is the most common cause 
of death among patients with AIDS, killing 1 of every 3 patients. HIV infection is the 
greatest single risk factor for developing TB. TB is the only major AIDS-related 
opportunistic infection that poses a risk to HIV-negative people. Collaboration 
between TB and HIV communities is essential in order to maximize access to existing 
effective interventions decreasing Tb in patients living with HIV. Data from WHO 
(Globalatlas) 2007.  CUTS data. 
 
4.2 Deaths due to HIV (AIDS): Death due to AIDS standardized death rate per 100 
000 inhabitants. Data from Eurostat 2007. CUTS data. 
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4.3 HIV prevalence in blood donations: Monitoring HIV prevalence in blood 
donations is important for surveillance as it provides an indication of the relative 
safety of the blood supply across countries and over time. In addition, it provides 
some Indication of HIV trends in the population, although trends in prevalence in 
blood donations are also clearly affected by changes in the effectiveness of donor. 
In order to prevent further dissemination of these infections through blood 
transfusion, it is important to establish a National Blood Transfusion Service based 
on non-paid, voluntary blood donors, and to ensure that regional hospitals are equally 
provided with safe blood. Blood donations in Europe are generally volunteer, and in 
order to prevent spreading of HIV and other diseases, potential donors are evaluated 
for anything that might make their blood unsafe to use. Data collected by EuroHIV 
2006. CUTS data 
 
4.4 Prevention MTCT: The policies in each country to prevent HIV vertical 
transmission. To measure the effectivity of the services provided (with some 
exceptions) it is measured as an outcome indicator “HIV infections newly diagnosed 
in persons infected through mother-to-child transmission per 100 000 live births”. 
Data was collected from the EuroHIV report available on 
http://www.eurohiv.org/reports/report_75/pdf/report_eurohiv_75.pdf   (2006). CUTS 
data 
4.5 Evidence of risk of HIV and HCV transmission in prison:  90% of countries 
could not provide data on this indicator. It was decided to include an indicator that 
could indirectly show if countries are putting in place specific policies to prevent, or 
at least monitor, the transmission of HIV and HCV in prison. Information on HIV and 
HCV testing performed at admission and before release of prison and if this kind of 
monitoring is done on a volunteer basis was collected. Data was collected from the 
prison health data base http://www.euro.who.int/prisons/20070221_1, and completed 
and corrected by personal interviews with heath care officials and experts in prisons. 
Non- CUTS Data. 
4.6 Proportion of patients on ART with Plasma viral load not detectable: Patients 
following the proper ART present undetectable plasma viral load. The data was 
collected through interviews with health officials and national bodies. Non CUTS 
data. 
 
7.7 Indicators, which would have been really nice to include 
7.7.1 Use of ART medication per person living with HIV 
The use of Anti-Retroviral Therapy (ART) medication per person living with HIV 
(PLWH) would have been a very interesting indicator to include. Data on ART 
medication are available, courtesy IMS Health (MIDAS). This data does have its small 
weaknesses, but the real problem turned out to be obtaining trustworthy data for the 
“number of PLWH” in each country. 
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The table below illustrates the truly Babel-like situation for this parameter – the published 
UNAIDS data frequently have confidence intervals which exceed ± 50% of the number 
given. Also, some countries (notably Italy and Spain) have dutifully reported deaths from 
HIV (which would be an underestimate, as many early PLWH will have died and had 
another cause of death recorded), but did not begin reporting number of HIV cases until 
2002 – 2003. Still, the number of reported deaths from HIV/AIDS for some countries far 
exceeds the accumulated number of PLWH. 
 
After many discussions with the HIV Index Expert Panel, is seemed that none of the 
sources quoted in the table above could be used for a reliable evaluation of the use of 
ART medication. The number of cases per country calculated from WHO numbers of 
PLWH per million population (numbers column #4, in brown) seemed to be the closest, 
but a comparison with countries having high quality national data shows underestimates 
for countries such as Denmark and, most certainly, Spain. 
The graph below shows the sales of ART medication per PLWH, with the HCP best 
estimate (“number the HCP could believe”) used as the denominator. As the uncertainties 
in this number are considerable, it could not be justified to include this as an indicator in 
the HIV index. However, it can serve as an illustration of what the data situation 
frequently is like in European healthcare, not restricted to HIV care. 
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If nothing else, the graph illustrates a typical process for scoring an indicator in a HCP 
Index, where in-data is numerical values. 
 
As has been observed for other classes of drugs, Luxembourg shows up in IMS Health MIDAS data with 
very low numbers. If this is because Luxembourgian patients are supplied from clinics in neighbouring 
countries, or because of other factors, is outside HCP knowledge. 
 
7.7.2 Which countries have been able (or lucky?) to curb the growth of HIV 
infection? 
HIV infection is still growing in Europe. However, the growth rate is different for 
different countries, and therefore it was considered of interest to see if an indicator could 
be based on the reported numbers of “New cases if HIV infection” (Source: WHO Health 
for All database, August 2009). 
In a comparison of a growth rate, the raw numbers of cases have to be converted into 
logarithmic values (in this case e-log values) to enable comparison of countries with very 
different levels of HIV prevalence (i.e. number of PLWH per million population). 
The result of this comparison is shown in the graph below: 
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The height of the bars shows the steepness of the trend line for “New cases of HIV infection”. Only 
Romania, Greece, Latvia and Denmark show a downward trend for this time period. If this parameter had 
been included as an indicator in the HIV Index, the bar colours show one conceivable way of scoring this 
indicator. 
Unfortunately, in addition to the uncertainty of HIV incidence reporting from various 
countries, there are additional confounding factors, which led to the decision not to 
include this parameter as an indicator in the HIV Index. One such strongly confounding 
factor would be that immigration rates from HIV high-prevalence parts of the world are 
extremely different across Europe. One example would most likely be the U.K., which 
has a very high continuous influx of immigrants from high-prevalence areas, which would 
tend to drag down the U.K. score on this indicator, even if the UK has good HIV 
prevention and care. 
7.8  This is how the HIV Index 2009 was built  
7.8.1  Strategy 
In April 2004 the HCP first launched the Swedish Health Consumer Index 
(www.vardkonsumentindex.se, also in a translation to English). By ranking the 21 county 
councils (the regional parliaments responsible for funding, purchasing and generally also 
providing healthcare) using 12 basic indicators concerning the design of “systems policy”, 
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consumer choice, service level, and access to information, we introduced benchmarking 
as an element in consumer empowerment.  
There is a pronounced need for improvement. The very strong media impact of the Index 
all over Sweden confirmed that the image of healthcare is rapidly moving from rationed 
public goods into consumer-related services measurable by common quality perspectives, 
For the Euro Health Consumer Indexes and for the HIV Index, the Health Consumer 
Powerhouse has been aiming to follow basically the same approach, i.e., selecting a 
number of indicators that describe to what extent the national healthcare systems are 
“user-friendly”, thus providing a basis for comparing different national systems.  
The Index does not take into account whether a national healthcare system is publicly or 
privately funded and/or operated. The purpose is health consumer empowerment, not the 
promotion of political ideology. Aiming for dialogue and co-operation, the ambition of 
HCP is to be looked upon as a partner in developing healthcare around Europe. 
7.9  Production phases 
The HIV Index 2009 was constructed under the following project plan. 
7.9.1  Phase 1 
Start-up meeting with the Expert Reference Panel (2008-12-9) 
Mapping of existing data  
The major area of activity was to evaluate to what extent relevant information is available and 
accessible for the selected countries. The basic methods were: 
• Web search, 
• Telephone and e-mail interviews with key individuals, and 
• Personal visits when required. 
 
Web search: 
a) Relevant byelaws and policy documents  
b) Actual outcome data in relation to policies 
 
Information providers: 
a) National and regional Health Authorities 
b) Institutions (EHMA, Cochrane Institute, Picker Institute, University of York Health 
Economics, others) 
c) Private enterprise (IMS Health, pharmaceutical industry, others) 
 
Interviews (to evaluate findings from earlier sources, particularly to verify the real outcomes of 
policy decisions): 
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a) Phone and e-mail 
b) Personal visits to key information providers 
7.9.2  Phase 2 
• Data collection to assemble presently available information to be included in the 
HIV Index 2009.  
• Identification of vital areas where additional information needed to be assembled 
was performed. 
• Collection of raw data for these areas 
• A round of personal visits by the researchers to Health Ministries and/or State 
Agencies for supervision and/or Quality Assurance of Healthcare Services. 
• We kept regular contact with the Expert Reference Panel mainly to discuss the 
indicators, the criteria to define them, and the data acquisition problems. We had a 
second meeting on July 1 in which we discuss in detail about each of the 
indicators, as well as the criteria used to define them. We also discuss the quality 
of the data collected and the results of the patient view survey. Finally, the points 
or reasons behind excluding some of the indicators and we looked altogether for 
possible alternatives or indicators that could reflect better the situation. 
• On September 23th was taking place the last meeting in which there was an active 
discussion about the waits and relevancy of each of the sub-disciplines included in 
the index as well as the discrepancies between data from different sources. 
7.9.3  Phase 3 
7.9.3.1  Consulting European patient advocates and citizens through HCP survey  
 performed by external research facility (Patient View, U.K.). 
The HIV Index survey contained the questions mentioned in Section 4.4.1 and is also 
found in Appendix 1 of this report. The survey was posted on the Internet in mid-March 
in Czech, English, French, German, Italian, Polish, Portuguese, Romanian, Spanish and 
Swedish. The closing date should have been April 29, but this was extended to June 23 
and until 5th of September for the French survey. In total 833 responses were submitted, 
and a total of 26 countries represented by more than 10 responses. The survey essentially 
has not been used as stand-alone data for any indicator, but as a reality check on 
policies and practice. 
7.9.3.2  “Score update sheet” send-out. 
On July 15, 2009, all 29 states received their respective preliminary score sheets (with no 
reference to other states’ scores) as an e-mail send-out asking for updates/corrections. The 
send-out was made to contacts at ministries/state agencies as advised by states during the 
contact efforts of the spring of 2009. Two reminders were also sent out. Corrective 
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feedback from states was accepted up until October 2nd, by which time replies had been 
received as listed in section 5.5.2 above. 
7.9.4  Phase 4 
Project presentation and reports 
• A report describing the principles of how the Euro HIV Index 2009 was 
constructed. 
• Presentation of the Euro HIV Index 2009 at various events on 2009-10-13 in 
Brussels and other venues in the following months. 
• On-line launch on www.healthpowerhouse.com . 
 
7.10  External expert reference panel 
As is the standard working mode for all HCP Indexes, an external Expert Reference Panel 
was recruited. The panel met for three 6-hour sittings during the course of the project, the 
Panel Members having been sent the Index working material in advance. The following 
persons have taken part in the Expert Reference Panel Work: 
Name Affiliation 
Frank Amort Aids Hilfe Wien (Austria) 
Nikos Dedes EATG  
Ulrik Bak Dragsted, MD, PhD Dept. of Infectious Diseases University of Copenhagen, Denmark 
Dr. Ian Hodgson School of Health Studies . University of Bradford, UK 
Jean-Claude Schmit, MD, 
PhD 
Centre de Recherche Public de la Santé (CRP-Santé), 
Luxembourg 
Dr. Danica Stanekova 
 
Slovak Medical University NRC for  HIV/AIDS prevention, 
Slovakia 
Dr. Berta Rodés Departamento de Enfermedades Infecciosas, Hospital Carlos III, 
Spain. 
Wim  Vandevelde Aids Action Europe  
 
The Expert Reference Panel for a HCP Index has two core tasks: 
A. To assist in the design and selection of sub-disciplines and indicators. This is 
obviously of vital importance for an Index, if the ambition is to be able to say that 
a state scoring well can truly be considered to have good, consumer-friendly 
healthcare services. 
B. To review the final results of research undertaken by HCP researchers before the 
final scores are set. If the information obtained seems to clash too violently with 
 46 
Health Consumer Powerhouse 
Euro HIV Index 2009 Report 
 
the many decades of cardiac care experience represented by the panel members, 
this has been taken as a strong signal to do an extra review of the results. 
The HCP wishes to extend its sincere thanks to the members of the panel for their 
fundamentally important contribution to the Index work, and for very valuable 
discussions. 
 
 
8.  References 
8.1   Main sources 
The main sources of input for the various indicators are given in Table 7.4 above. For all 
indicators, this information has been supplemented by interviews and discussions with 
healthcare officials in both the public and private sectors and by data from national 
registries and communication from national Ministries of Health, state agencies, 
researchers, experts in infectious diseases, different kinds of associations and 
organizations, experts in prisons, etc… 
 
8.2  Useful links 
Web search exercises have yielded useful complementary information from. Below is a 
list of some these sources. 
 
Links to trans-national data 
European Monitoring Center for Drugs and Drugs addiction http://www.emcdda.europa.eu/
about  
European Monitoring Center for Drugs and Drugs addiction (Country reports) http://www.emcdda.europa.eu/pu
blications/searchresults?action=lis
t&type=PUBLICATIONS&SERI
ES_PUB=w203&CFID=2983402
&CFTOKEN=1c27295f9d5b1867
-26AA39D4-9AA7-B399-
2ED0085498D8B37B&jsessionid
=38304266260ea8be44805a1f157
021745b6a  
The People living with HIV stigma index http://www.stigmaindex.org   
UNAIDS http://www.unaids.org/en/   
Sexuality education in Europe (Safe Project) http://www2.hu-
berlin.de/sexology/BIB/SexEd
/SexEd.html  
PICUM http://www.picum.org/   
Prison health data base http://www.euro.who.int/priso
ns/20070221_1  
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Aids Action Europe http://www.aidsactioneurope.o
rg/ 
Commercial sex information Service http://www.walnet.org/csis/gro
ups/index.html  
TAMPED http://www.tampep.com/  
CISID http://data.euro.who.int/cisid/  
ECDC http://ecdc.europa.eu/  
Interactive map towards universal access 
 
http://www.unaids.org/en/Kno
wledgeCentre/HIVData/mappi
ng_progress.asp    
HIV Europe http://www.hiveurope.org/  
AIDS foundation East and West http://www.afew.org/index.ph
p?id=cetest_firstpage  
Copenhagen HIV programme http://www.cphiv.dk/CHIP/tab
id/36/Default.aspx  
Euro Tuberculosis http://www.eurotb.org/  
WHO Tuberculosis http://www.who.int/topics/tube
rculosis/en/  
GNP+ http://www.gnpplus.net/crimin
alisation/index.php?option=co
m_content&task=view&id=21
&Itemid=42  
AVERT http://www.avert.org/hiv-aids-
europe.htm  
Patient View http://www.patient-
view.com/hscnetwork.htm 
Eurosurveillance http://www.eurosurveillance.or
g/Public/RSSFeed/RSS.aspx?k
eyword=acquired%20immono
deficiency%20syndrome%20-
%20AIDS  
EuroHIVnursing http://www.eurohivnursing.net
/index.html  
HIV/AIDS survey Indicators Data base http://www.measuredhs.com/hi
vdata/ind_tbl.cfm  
Eurobarometer http://ec.europa.eu/public_opi
nion/archives/eb_special_en.ht
m  
WHO health Atlas http://apps.who.int/globalatlas/
predefinedreports/tb/index.asp  
AIDS and Mobility Europe http://www.aidsmobility.org/in
dex.cfm?fuseaction=Pages.sho
wPages&code=319  
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Border Net http://www.bordernet-spi.de/  
Access to Care: Privilege or Right? 
Migration and HIV : Vulnerability in Europe 
http://aidsactioneurope.org/upl
oads/tx_windpublications/106.
pdf  
Diagnosed and undiagnosed HIV-infected populations in Europe http://www3.interscience.wiley
.com/journal/120092161/abstr
act?CRETRY=1&SRETRY=0  
EuroSIDA http://www.cphiv.dk/EuroSID
A/tabid/59/Default.aspx  
EURO Support V and VI: Improving the Sexual and Reproductive Health of 
Persons Living with HIV 
http://www.itg.be/eurosupp/  
Antenatal HIV screening in Europe: a review of policies 
 
file:///C:/Documents%20and%
20Settings/Administrador/Escr
itorio/Important%20papers/ant
enatal%20HIV%20screening
%20in%20Europe.htm  
UNGASS - National Composite Policy Index (NCPI) 2007 Europe 
http://www.unaids.org/en/Kno
wledgeCentre/HIVData/Count
ryProgress/2008_NCPI_report
s.asp  
Country-wide distribution of the nitrile female condom (FC2) in 
Brazil and South Africa: a cost-effectiveness analysis. 
http://www.ncbi.nlm.nih.gov/si
tes/entrez?cmd=Retrieve&db=
PubMed&list_uids=17053355  
Impact of Sex & HIV Curriculum-based Education Programmes on Sexual 
Behavior of Youth in Developing Co. Washington, DC: Family Health 
International. 
http://programmeservices.etr.o
rg/index.cfm?fuseaction=about
.StaffSummary&StaffID=28  
Migration and HIV/AIDS: community recommendations http://www.eatg.org/eatg/The-
right-to-HIV-AIDS-
prevention-treatment-care-and-
support-for-migrants-and-
ethnic-minorities-in-Europe-
The-community-perspective-
2007-2008 
 
Links to national data 
Austria Aids Hilfe Wien www.aidshilfen.at  
Belgium Sensoa http://www.sensoa.be/  
Bulgaria Commission against discrimination http://www.kzd-
nondiscrimination.com/  
Bulgaria Country information  http://www.unaids-
bulgaria.org/index.php?magic
=0.197  
Bulgaria National strategy and programme for profylaxis and control of 
HIV and STIs 2001-2007 
(http://www.aidsbg.info/attach
ment/47/Natzionalna%20progr
ammea%202001-2007.doc  
 49 
Health Consumer Powerhouse 
Euro HIV Index 2009 Report 
 
Bulgaria National committee on AIDS and sexually transmitted infectious 
prevention, Ministry of Health 
(http://www.ncaids.governmen
t.bg/  
CZ General information for PLWH http://www.szu.cz/  
Denmark Discriminiation and stigma http://www.levekaar.dk/  
Germany  AIDS prevention http://www.bzga.de/bot_Seite1
649.html  
Germany  Education for sex workers www.highlits-berlin.de  
Lithuania Access to care for migrants www.vlk.lt  
Lithuania HIV/AIDS in Lithuania www.sam.lt  
Lithuania HIV/AIDS in Lithuania http://old.aids.lt/index.en.php  
Cyprus HIV/AIDS : The Situation in Cyprus and the World  
 
http://www.moh.gov.cy/moh/moh
.nsf/All/2EABFB2BB47FDA22C
2256E4400328C7B/$file/HIV_AI
DS%20WORLDWIDE03_ENG.p
df?OpenElement  
France Harm reduction and equity of access to care for French 
prisoners: a review 
http://www.pubmedcentral.nih.
gov/articlerender.fcgi?artid=2
430551  
Estonia Discrimination and Stigma http://www.tai.ee/failid/HIV_p
os_uurimuse_raport_20.07.20
06.pdf  
Estonia AIDS information and support center http://www.convictus.ee/index.
php/en  
Estonia HIV in Estonia http://www.tai.ee/?id=4043  
Estonia Access to Post-Exposure-Prophylaxis http://www.tervishoiuamet.ee/
public/files/HIV_kokkupuutej
uhtum_eestikeeles.pdf  
Estonia National Drug prevention stategy 2012 http://www.irishaid.gov.ie/arti
cle.asp?article=899  
Ireland Stigma and discrimination http://www.irishaid.gov.ie/arti
cle.asp?article=899  
Ireland Access to lipodystrophy treatment http://www.pozireland.org/lipo
dystrophy.htm  
Netherlands HIV monitoring fundation www.hiv-monitoring.nl  
Spain   CESIDA http://www.cesida.org/  
Spain Plan sida http://www.msps.es/ciudadano
s/enfLesiones/enfTransmisible
s/sida/home.htm  
Switzerland Swiss HIV Cohort Study www.shcs.ch 
Switzerland Bundesamt für gesundheit www.bag.admin.ch/aids 
Switzerland Pärli K, Caplazi A, Suter C. Recht gegen HIV/Aids-
Diskriminierung im Arbeitsverhältnis.Eine rechtsvergleichende 
Untersuchung zur Situation in Kanada, Grossbritannien, 
Frankreich, Deutschland und der Schweiz 
http://www.non-
discrimination.fhso.ch/F-
Paerli-
Diskriminierungsschutz.pdf 
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UK National Strategy for Sexual Health and HIV http://www.dh.gov.uk/en/Publi
cationsandstatistics/Publicatio
ns/PublicationsPolicyAndGuid
ance/DH_4003133 
UK HIV in the United Kingdom: 2008 Report http://www.hpa.org.uk/webw/
HPAweb&HPAwebStandard/
HPAweb_C/1227515299695  
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Appendix 1. Questionnaire used in the survey commissioned 
from Patient View for the Euro HIV Index 2009. 
The compiler of the annual EuroHealth Consumer Index, the Brussels and Stockholm-based 
HEALTH CONSUMER POWERHOUSE (HCP), has now started looking at how well each country in 
Europe treats individual diseases. 
HIV/AIDs is one of the first such diseases to be examined by HCP. 
The questionnaire below ALLOWS YOU TO CONTRIBUTE YOUR VIEWS to HCP’s forthcoming 
EURO HIV INDEX2009. The questionnaire is very short — only 6 questions, preceded by some 
brief profiling questions. Filling in the questionnaire should take you no more than about 5-10 
minutes. 
The survey is being conducted online on this specialist survey site, so allowing all responses to 
be completely ANONYMOUS. No IP addresses or email details can reach the survey managers 
(unless you choose to mention such information in the survey). 
If, however, you would like to be sent the weblink to the completed Euro HIV Index2009 when 
it is published later in 2009, you can specify CONTACT DETAILS for that at the end of the 
questionnaire. 
The survey will close on Tuesday, June 23th 2009 (but we would welcome your input earlier 
than that, as your opinions can help to quickly establish some trends). 
Health Consumer Powerhouse would like to thank Gilead for an unrestricted grant that covers 
the costs of producing the Euro HIV Index2009. 
The survey is being administered by Patient View (a UK-based publishing and research 
organisation) on behalf of Health Consumer Powerhouse. Should you have any questions 
regarding this survey, please do not hesitate to contact the survey administrator: 
Louise Oatham, 
'HCP HIV survey 2009', 
PatientView, Woodhouse Place, Upper Woodhouse, Knighton, Powys, LD7 1NG, UK. 
info@patient-view.com 
Tel: 0044-(0)1547-520-965 
 
Question 1/6: 
Is refusal of medical care from non-HIV medical professionals a FREQUENT problem  
in your country (dental care included)? 
 Yes, definitely. 
 Not frequently, but it does happen. 
 No, this would be a minimal problem. 
 I do not know.  
If "Yes", what specialty/specialties tend to refuse treatment? 
[Please specify only one option] 
 
Question 2/6: 
In your country, do the following types of marginalised people living with HIV receive  
care, support, and treatment EQUIVALENT to that available to all other people living  
with HIV? 
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Yes.      Sometimes.    Only through NGOs.    No.     I do not know. 
 Illegal migrants. 
 Prisoners. 
 Sex workers. 
 
 
Question 3/6: 
How often do people with HIV in your country get screened for STIs and hepatitis? 
 More than once a year. 
 Once a year. 
Less than once a year. 
 Only if the person themself takes the initiative to have a test. 
 People with HIV do not get screened for STIs and hepatitis. 
 I do not know. 
 
Question 4/6: 
Is surgery available for lipodystrophy in your country? [Lipodystrophy is a lack or loss of 
subcutaneous fat - a possible side effect of antiretroviral drugs.]  
[Please specify only one option] 
 
 Yes, it is free, and the patient DOES NOT have to mention their HIV status to anyone other   
than the surgeon. 
 Yes, it is free - but the patient MAY HAVE TO mention their HIV status to people other than the 
surgeon (such as a general practitioner, local healthcare authority, reimbursement authority, etc). 
 It is only available privately. 
 No. 
 I do not know. 
  
Question 5/6: 
Can people with HIV in your country experience stigma or discrimination in any of the 
following settings, or from any of the following individuals?  
Yes.               Sometimes.         No.           I do not know. 
 At school. 
 At work. 
 In the street. 
 From healthcare personnel who specialise in HIV. 
 From healthcare personnel who DO NOT specialise in HIV. 
 From friends who have HIV. 
 From friends who DO NOT have HIV. 
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 From sex partners who have HIV. 
 From sex partners who DO NOT have HIV. 
 
Question 6/6: 
Are people with HIV in your country subject to restrictions on entering/using either of the 
two following public facilities? 
Yes, by law. 
Yes, if the facility has special rules for people with infectious diseases. 
No. I do not know 
 Swimming pools. 
 Public transport. 
 
(If you know of any restrictions in any other public facilities, could you please mention them here). 
 
 
 
 
 
 

